Development of inhibitors for protein tyrosine kinases

Fahad A. Al-Obeidi, Kit Lam

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

In the last 5 years, through combinatorial chemistry, high-throughput screening, computational chemistry, and traditional medicinal chemistry, numerous inhibitors for various protein tyrosine kinases (PTKs) have been developed. The majority of these compounds are small molecules that compete at the ATP binding site of the catalytic domain of the enzymes. Some compounds such as pseudosubstrate-based peptide inhibitor binds to the peptide/protein substrate site of the catalytic domain. Some inhibitors, primarily monoclonal antibodies, bind to the extracellular domain of receptor tyrosine kinases. Some of these inhibitors are highly potent and selective. Several are currently undergoing clinical trials for a number of diseases such as cancer.

Original languageEnglish (US)
Pages (from-to)5690-5701
Number of pages12
JournalOncogene
Volume19
Issue number49
StatePublished - Nov 20 2000

Fingerprint

Protein-Tyrosine Kinases
Catalytic Domain
Peptides
Pharmaceutical Chemistry
Receptor Protein-Tyrosine Kinases
Adenosine Triphosphate
Binding Sites
Monoclonal Antibodies
Clinical Trials
Enzymes
Neoplasms
Proteins

Keywords

  • Cancer therapy
  • Clinical studies
  • Drug development
  • Inhibitors
  • Preclinical studies
  • Protein tyrosine kinase

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Development of inhibitors for protein tyrosine kinases. / Al-Obeidi, Fahad A.; Lam, Kit.

In: Oncogene, Vol. 19, No. 49, 20.11.2000, p. 5690-5701.

Research output: Contribution to journalArticle

Al-Obeidi, FA & Lam, K 2000, 'Development of inhibitors for protein tyrosine kinases', Oncogene, vol. 19, no. 49, pp. 5690-5701.
Al-Obeidi FA, Lam K. Development of inhibitors for protein tyrosine kinases. Oncogene. 2000 Nov 20;19(49):5690-5701.
Al-Obeidi, Fahad A. ; Lam, Kit. / Development of inhibitors for protein tyrosine kinases. In: Oncogene. 2000 ; Vol. 19, No. 49. pp. 5690-5701.
@article{2e0ba1e7969248908e73a219fa46a4f3,
title = "Development of inhibitors for protein tyrosine kinases",
abstract = "In the last 5 years, through combinatorial chemistry, high-throughput screening, computational chemistry, and traditional medicinal chemistry, numerous inhibitors for various protein tyrosine kinases (PTKs) have been developed. The majority of these compounds are small molecules that compete at the ATP binding site of the catalytic domain of the enzymes. Some compounds such as pseudosubstrate-based peptide inhibitor binds to the peptide/protein substrate site of the catalytic domain. Some inhibitors, primarily monoclonal antibodies, bind to the extracellular domain of receptor tyrosine kinases. Some of these inhibitors are highly potent and selective. Several are currently undergoing clinical trials for a number of diseases such as cancer.",
keywords = "Cancer therapy, Clinical studies, Drug development, Inhibitors, Preclinical studies, Protein tyrosine kinase",
author = "Al-Obeidi, {Fahad A.} and Kit Lam",
year = "2000",
month = "11",
day = "20",
language = "English (US)",
volume = "19",
pages = "5690--5701",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "49",

}

TY - JOUR

T1 - Development of inhibitors for protein tyrosine kinases

AU - Al-Obeidi, Fahad A.

AU - Lam, Kit

PY - 2000/11/20

Y1 - 2000/11/20

N2 - In the last 5 years, through combinatorial chemistry, high-throughput screening, computational chemistry, and traditional medicinal chemistry, numerous inhibitors for various protein tyrosine kinases (PTKs) have been developed. The majority of these compounds are small molecules that compete at the ATP binding site of the catalytic domain of the enzymes. Some compounds such as pseudosubstrate-based peptide inhibitor binds to the peptide/protein substrate site of the catalytic domain. Some inhibitors, primarily monoclonal antibodies, bind to the extracellular domain of receptor tyrosine kinases. Some of these inhibitors are highly potent and selective. Several are currently undergoing clinical trials for a number of diseases such as cancer.

AB - In the last 5 years, through combinatorial chemistry, high-throughput screening, computational chemistry, and traditional medicinal chemistry, numerous inhibitors for various protein tyrosine kinases (PTKs) have been developed. The majority of these compounds are small molecules that compete at the ATP binding site of the catalytic domain of the enzymes. Some compounds such as pseudosubstrate-based peptide inhibitor binds to the peptide/protein substrate site of the catalytic domain. Some inhibitors, primarily monoclonal antibodies, bind to the extracellular domain of receptor tyrosine kinases. Some of these inhibitors are highly potent and selective. Several are currently undergoing clinical trials for a number of diseases such as cancer.

KW - Cancer therapy

KW - Clinical studies

KW - Drug development

KW - Inhibitors

KW - Preclinical studies

KW - Protein tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=0034693811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034693811&partnerID=8YFLogxK

M3 - Article

C2 - 11114749

AN - SCOPUS:0034693811

VL - 19

SP - 5690

EP - 5701

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 49

ER -